The debut of troglitazone, a potent antidiabetic agent, marked a important chapter in the treatment of type 2 diabetes. However, its removal from the market due to substantial hepatotoxicity spurred broad investigation into related thiazolidinediones. Following pioglitazone and rosiglitazone emerged, offering akin mechanisms of action – primarily